Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
NovoCure Limited - Ordinary Shares
(NQ:
NVCR
)
14.94
-0.98 (-6.16%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about NovoCure Limited - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
October 01, 2026
From
Novocure
Via
Business Wire
Novocure to Report Third Quarter 2026 Financial Results
October 01, 2026
From
Novocure
Via
Business Wire
Novocure Announces Upcoming Investor Events
September 02, 2026
From
Novocure
Via
Business Wire
Novocure Reports Second Quarter 2026 Financial Results
July 23, 2026
From
Novocure
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
July 14, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
July 07, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Novocure to Report Second Quarter 2026 Financial Results
July 01, 2026
From
Novocure
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
June 30, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
June 30, 2026
From
Novocure
Via
Business Wire
NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm
June 20, 2026
From
The Schall Law Firm
Via
Business Wire
Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma
June 18, 2026
From
Novocure
Via
Business Wire
Novocure Reports First Quarter 2026 Financial Results
April 30, 2026
From
Novocure
Via
Business Wire
Novocure to Report First Quarter 2026 Financial Results
April 01, 2026
From
Novocure
Via
Business Wire
Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer
March 26, 2026
From
Novocure
Via
Business Wire
Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
March 02, 2026
From
Novocure
Via
Business Wire
Novocure to Participate in 2026 Leerink Global Healthcare Conference
February 27, 2026
From
Novocure
Via
Business Wire
Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
February 26, 2026
From
Novocure
Via
Business Wire
Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)
February 24, 2026
From
Novocure
Via
Business Wire
U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer
February 11, 2026
From
Novocure
Via
Business Wire
Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update
January 12, 2026
From
Novocure
Via
Business Wire
Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference
December 22, 2025
From
Novocure
Via
Business Wire
Novocure Appoints Company President Frank Leonard as Chief Executive Officer
December 01, 2025
From
Novocure
Via
Business Wire
Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference
November 26, 2025
From
Novocure
Via
Business Wire
Novocure to Participate in 2025 Jefferies Global Healthcare Conference
November 12, 2025
From
Novocure
Via
Business Wire
Novocure Reports Third Quarter 2025 Financial Results
October 30, 2025
From
Novocure
Via
Business Wire
Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress
October 15, 2025
From
Novocure
Via
Business Wire
Novocure to Report Third Quarter 2025 Financial Results
October 01, 2025
From
Novocure
Via
Business Wire
Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting
September 29, 2025
From
Novocure
Via
Business Wire
Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)
September 15, 2025
From
Novocure
Via
Business Wire
Novocure Announces Upcoming Investor Events
August 28, 2025
From
Novocure
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
